Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 414

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 414
---
 shares authorized; 6,900,000 shares issued and outstanding (excluding 238,930 and 406,609 shares subject to possible redemption, respectively) at September 30, 2024 and December 31, 2023 | ​ | ​ | ​                  | ​ |         690 | ​ | ​ | ​ | ​                 | ​ |         690 | ​ | ​ |
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023                                                                                              | ​ | ​ | ​                  | ​ |           — | ​ | ​ | ​ | ​                 | ​ |           — | ​ | ​ |
| Extension deposits due from Sponsor                                                                                                                                                                                                             | ​ | ​ | ​                  | ​ |    -117,669 | ​ | ​ | ​ | ​                 | ​ |           — | ​ | ​ |
| Additional paid-in capital                                                                                                                                                                                                                      | ​ | ​ | ​                  | ​ |      52,287 | ​ | ​ | ​ | ​                 | ​ |     140,000 | ​ | ​ |
| Accumulated deficit                                                                                                                                                                                                                             | ​ | ​ | ​                  | ​ | -16,642,469 | ​ | ​ | ​ | ​                 | ​ | -14,883,124 | ​ | ​ |
| Total Stockholders’ Deficit                                                                                                                                                                                                                     | ​ | ​ | ​                  | ​ | -16,707,161 | ​ | ​ | ​ | ​                 | ​ | -14,742,434 | ​ | ​ |
| Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Deficit                                                                                                                                                        | ​ | ​ | ​                  | $ |   3,068,186 | ​ | ​ | ​ | ​                 | $ |   4,502,213 | ​ | ​ |

(1) As of September 30, 2024 and December 31, 2023, include $32,580 and $85,084, respectively of the restricted cash to be used for tax payments only.

The accompanying notes are an integral part of these unaudited condensed financial statements. F-2

TABLE OF CONTENTS

IRIS ACQUISITION CORP CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)

| ​                                                                                                          | ​ | ​ | Three Months EndedSeptember 30,2024